Most cancer cells exhibit increased glycolysis for generation of their energy supply. This specificity could be used to preferentially kill these cells. In this study, we identified the signaling pathway initiated by glycolysis inhibition that results in sensitization to death receptor (DR)-induced apoptosis. We showed, in several human cancer cell lines (such as Jurkat, HeLa, U937), that glucose removal or the use of nonmetabolizable form of glucose (2-deoxyglucose) dramatically enhances apoptosis induced by Fas or by tumor necrosis factor-related apoptosis-inducing ligand. This sensitization is controlled through the adenosine monophosphate (AMP)-activated protein kinase (AMPK), which is the central energy-sensing system of the cell. We established the fact that AMPK is activated upon glycolysis block resulting in mammalian target of rapamycin (mTOR) inhibition leading to Mcl-1 decrease, but no other Bcl-2 anti-apoptotic members. Interestingly, we determined that, upon glycolysis inhibition, the AMPK-mTOR pathway controlled Mcl-1 levels neither through transcriptional nor through posttranslational mechanism but rather by controlling its translation. Therefore, our results show a novel mechanism for the sensitization to DR-induced apoptosis linking glucose metabolism to Mcl-1 downexpression. In addition, this study provides a rationale for the combined use of DR ligands with AMPK activators or mTOR inhibitors in the treatment of human cancers.
Introduction
Members of the tumor necrosis factor super family have a central role in normal and pathological conditions (Takeda et al., 2007) . Among them, CD95 (Fas/Apo-1) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are potent activators of the apoptotic pathway in response to their specific ligand. Interestingly, tumor cells express significant levels of death receptors (DRs) on their surface; however, these levels do not necessarily correlate with sensitivity to the death signal (Luciano et al., 2002) .
Since Warburg's work in 1929, it has been evident that cancer cells very frequently upregulate glucose metabolism leading to a high uptake and use of glucose, but moderate rates of mitochondrial respiration, under aerobic conditions. This specificity is used by positron emission tomography for the detection of primary and metastatic tumors in patients (Gambhir, 2002) . Frequently, the upregulation of glycolytic metabolism correlates with increased tumor aggressiveness and poor patient prognosis (Detterbeck et al., 2004) . Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a central energy-sensing system that acts as a fuel gauge by monitoring cellular energy levels (Long and Zierath, 2006) . When adenosine triphosphate (ATP) levels decrease below a threshold value, AMPK phosphorylates and activates the tuberous sclerosis complex 1/2 that inhibits the RHEB G-protein, which in turn activates the mammalian target of rapamycin (mTOR) (Inoki et al., 2003) . The main function of mTOR is to regulate protein translation by direct phosphorylation of key translation regulators p70 ribosomal S6 kinase (p70-S6K) and eukaryotic initiation factor (eIF)4E-binding protein (4E-BP) (for review, see Corradetti and Guan (2006) ). Recent advances in cancer research have drawn increased interest in the use of mTOR inhibitors to treat various cancers. Indeed, rapamycin was shown to sensitize cancer cells to cytotoxic therapies (Wendel et al., 2004) , and some rapamycin analogs are in clinical development for cancer treatment (Amaravadi and Thompson, 2005) .
Several lines of evidence are suggesting that glucose metabolism could have a key role in DR-induced apoptosis. In vitro and in vivo studies have indicated that tumor necrosis factor-a-induced toxicity is exacerbated in tumor cells under conditions of low glucose metabolism (Volland et al., 1992; Halicka et al., 1995) . These studies have led some investigators to use a nonmetabolizable form of glucose (2-deoxyglucose, 2DG) in combination with tumor necrosis factor-a as a possible antitumor treatment (Halicka et al., 1995) . It has also been suggested that Bcl-2 family members are involved in the regulation of cell death during glucose withdrawal. The Bcl-2 family is composed of proapoptotic and antiapoptotic members controlling mitochondrial permeabilization (Chipuk et al., 2006) . Glucose removal, by acting on the cell metabolic status, has been reported to activate the proapoptotic member, Bax (Chi et al., 2000; Vander Heiden et al., 2001) . However, the link between Bcl-2 family and glucose metabolism remains unclear. The exact mechanism remains to be revealed as several studies are describing conflicting results (Eguchi et al., 1997; Leist et al., 1997; Ferrari et al., 1998) .
For these reasons, we addressed the effect of glucose metabolism inhibition on DR-induced apoptosis (Fas and TRAIL receptors). We observed that glycolysis inhibition (by glucose removal or by the use of 2DG) leads to an enhancement of DR-induced apoptosis in Jurkat, U937 and HeLa cells. This sensitization is mediated by a decrease in ATP content resulting in AMPK activation and mTOR inhibition, culminating in the reduction of Mcl-1 levels through a block of its translation. Therefore, this AMPK-mTOR-dependent loss of Mcl-1 could explain how the inhibition of glucose metabolism (by a mitochondrial amplification of the cell death signal) enhances DR-induced apoptosis. Interestingly, we established that glucose removal sensitization to DR-induced apoptosis could be mimicked by AMPK activators (such as metformine and 5-aminoimidazole-4-carboxamide-1-b-d-ribofuranoside (AICAR)) or by the mTOR inhibitor (such as rapamycin), suggesting a rationale for the combined use of these drugs with DR ligands in the treatment of human cancers.
Results

Inhibition of glucose metabolism enhances Fas and TRAIL-induced apoptosis
To determine whether modification in glucose metabolism could impact DR-induced apoptosis, we analyzed the effect of glucose removal on Fas and TRAILinduced death. For that matter, Jurkat cells were cultured in glucose-free medium (supplemented as described in the 'Materials and methods' section) for 16 h, and then the cells were either left untreated (indicated as '0') or incubated in the presence of a sublethal concentration of anti-Fas antibody as indicated ( Figure 1a) . A three-to four-fold increase in the percentage of Annexin V/propidium iodide-positive cells was evidenced under low glucose condition versus control. This increase correlated very closely with that in caspase activity observed in the absence of glucose (Figure 1b) . It is noteworthy that glucose removal on its own did not induce death in this setting (see black histograms in '0' conditions in Figures 1a-e) . We extended this observation to TRAIL-induced apoptosis ( Figure 1c ) and verified that this sensitization was not due to a differential expression of several DRs (Supplementary Figure 1) . We established that sensitization of DR-induced apoptosis could be observed in glucose-free conditions and in the presence of a nonmetabolizable glucose analog, 2DG (Figure 1d ). Finally, we extended these observations to two other cancer cell lines HeLa and U937 (Figure 1e ). These results suggest that glycolysis inhibition can sensitize cells to DR-induced apoptosis.
Glucose removal or 2DG, sensitizes cells to DR-induced apoptosis through AMPK activation and mTOR inhibition As most cancer cells are strictly dependent on glycolysis for their energy production, glucose removal or the use of 2DG will mainly shut down ATP production in these cells. Therefore, we speculated whether the energetic status of the cell would impact DR-induced apoptosis. We verified that glucose removal or 2DG treatment leads to a marked decrease in cellular ATP content (Figure 2a) , which is associated with a reduction in lactate production (one of the byproducts of aerobic glycolysis in cancer cells, Figure 2b ). More interestingly, increasing pyruvate concentration by five times (pyruvate was provided as a carbon source to the cells) could prevent the decrease in ATP content ( Figure 2c ) and abolish the previously observed cell death sensitization (Figure 2d ). These findings suggested that cell metabolism could influence DR-induced apoptosis.
The AMPK is a central energy-sensing system activated when cellular AMP/ATP ratio increases. Therefore, we verified that glycolysis block led to AMPK activation (that is, phosphorylation, Figure 3a ). To test whether its activation was involved in the observed sensitization to DR-induced death, we used two different AMPK activators (namely AICAR and metformin). As presented in Figures 3b and c , both drugs mimicked, in glucose containing media, the sensitization to DR-induced apoptosis observed under low glucose conditions. AMPK involvement was further confirmed using an AMPK inhibitor (compound C), which could prevent in a dose-dependent manner the sensitization to DR-induced apoptosis observed under low glucose conditions ( Figure 3d ). As AMPK activation will lead to mTOR shut down, we visualized mTOR inhibition upon glycolysis block by observing the decrease in p70-S6K phosphorylation (Figure 3a) . The implication of mTOR inhibition in sensitization was confirmed by the fact that rapamycin (mTOR inhibitor) was able to sensitize cells to DR-induced death (Figure 3e ). It is noteworthy that none of the drugs used presents significant toxicity on their own. Therefore, our data suggested that sensitization to DRinduced apoptosis by glucose removal occurred through AMPK activation and consequently through mTOR inhibition.
Sensitization to DR-induced apoptosis by glucose metabolism inhibition is mediated by Mcl-1 downregulation Scaffidi et al. (1999) have previously shown that the mitochondrial pathway is required for DR-induced apoptosis in Jurkat cells. On the basis of this, we identified where in the apoptosis pathway glucose metabolism may impact DR-induced death. To determine whether the sensitization induced by glucose removal was acting upstream or downstream of the mitochondria, we used Jurkat cells stably overexpressing the antiapoptotic protein Bcl-2. As shown in Figure 4a , even with high concentration of anti-Fas antibody, sensitization upon glucose removal cannot be obtained in Bcl-2 overexpressing cells in the absence of glucose, whereas it was clearly seen in control cells. Hence, we concluded that the mitochondria control a crucial step in the sensitization to DR-induced apoptosis by glycolysis inhibition.
For this reason, we hypothesized that glucose metabolism could act on Bcl-2 family proteins. Among those, Mcl-1 is of great interest as it has been described as being a link between glucose metabolism and the Bcl-2 family in other contexts (Alves et al., 2006; Zhao et al., 2007) . Mcl-1 levels, but not Bcl-XL or Bcl-2 levels, were found to be largely altered (by 48-66%) upon glycolysis inhibition (Figure 4b ). Mcl-1 decrease upon glucose removal or with 2DG was confirmed in HeLa and U937 Figure 1 Glucose deprivation sensitizes cancer cells to death receptor-induced apoptosis. (a) Jurkat cells were cultured in control or in glucose-free media during 16 h, the cells were then incubated with anti-Fas antibody (CH11: 10 ng/ml) for 2-8 h or left in the corresponding media for total period of 24 h (noted as '0'). Percentage of apoptotic cells was assessed by Annexin V/PI staining. (b) Treatment as in panel a. DEVDase activity was measured using Ac-DEVD-AMC. (c) Jurkat cells were cultured and analyzed as in panel a. Apoptosis was induced using recombinant TRAIL (10 ng/ml) incubated during the indicated time. (d) Jurkat cells were cultured in control, glucose-free media or in media containing 10 mM of 2-deoxyglucose (2DG) for 16 h and then treated with 10 ng/ml of anti-Fas as indicated. Percentage of apoptotic cells was assessed as in panel a. (e) HeLa and U937 cells were cultured in normal, glucose-free or in media containing 2DG. Apoptosis was then induced using anti-Fas antibody (CH11, 50 ng/ml) or TRAIL (100 ng/ ml) for 6 h and assessed using Annexin V/PI staining. Results represent mean±s.d. of three independent experiments. PI, propidium iodide; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand. Figure 2) . We next verified whether AMPK activators (using AICAR or metformin, Figures 4c and d) or an mTOR inhibitor (rapamycin, Figure 4e ) were indeed leading to Mcl-1, but not to Bcl-XL, decrease. Subsequently, we speculated whether Mcl-1 downregulation was required for the sensitization to DR-induced death upon glycolysis inhibition. For this, we used specific Mcl-1 small interfering RNAs (siRNAs) ( Figure 5a ) and observed that in glucose containing media, Mcl-1 knockdown was sufficient to sensitize cells to Fas-induced apoptosis to the same extent than upon glucose removal (Figure 5b ).
cells (Supplementary
Therefore, these observations indicated that inhibition of glucose metabolism led to a specific decrease in Mcl-1 levels, which represent a key event in the sensitization to DR-induced apoptosis.
Mcl-1 downregulation through glycolysis block is neither mediated by a transcriptional nor by a posttranslational modification Finally, to understand how this Mcl-1-specific downregulation could occur, we analyzed the Mcl-1 mRNA level by real-time PCR. No significant differences could be measured comparing conditions with normal to low glucose content (Figure 6a ), therefore excluding a transcriptional regulation. Several mechanisms were described regarding the regulation of Mcl-1 protein levels. One is Mcl-1 cleavage by caspases during apoptosis (Herrant et al., 2004) . Despite the fact that no caspase activity could be measured during glucose removal alone (Figure 1b) , we tested the possibility that a weak caspase activity could somehow lead to the observed Mcl-1 decrease. As depicted in Figure 6b , a pan-caspase inhibitor (qVD-OPH) could not prevent Mcl-1 decrease during glucose removal. By contrast and as expected, qVD-OPH could prevent Mcl-1 cleavage observed during staurosporin-induced caspase activation. Therefore, caspase cleavage of Mcl-1 was very unlikely to be involved in the observed decrease in the protein level.
Another central mechanism controlling Mcl-1 levels is mediated by its ubiquitination and proteasomal degradation (Zhong et al., 2005; Maurer et al., 2006) . Therefore, we monitored Mcl-1 levels in the presence of the proteasome inhibitor MG132. As presented in Figure 6c , the profound decrease in Mcl-1 protein levels that could be observed in the absence of glucose was not prevented in the presence of MG132. As a longer MG132 treatment is toxic for the cells (Nencioni et al., 2005) , we combined MG132 with qVD-OPH for the time of glucose starvation, that is, overnight (Figure 6d ). Even under these conditions, Mcl-1 levels could not be significantly maintained upon glucose removal compared with glucose control media. Recently, it has been shown that glycogen synthase kinase (GSK)-3 phophorylation of Mcl-1 leading to its degradation by proteasome was an important pathway controlling Mcl-1 expression (Maurer et al., 2006) , especially upon modification of the glycolytic pathway (Zhao et al., 2007) . To test the potential implication of this pathway, we monitored GSK-3 activation upon glucose removal. No modification of phospho-GSK-3 (inactive form of GSK-3) could be observed in our settings (Supplementary Figure 3a) . In addition, none of the GSK-3 inhibitors used (TDZD-8 and CT99021) could prevent the sensitization (Supplementary Figures 3b-c) , therefore excluding a role of this pathway.
We next verified that glucose removal did not interfere with the clearance of Mcl-1 protein. As presented in Figure 6e (and quantified in Figure 6f ) even if less Mcl-1 was observed in low glucose conditions, the rate of Mcl-1 clearance was not significantly affected in normal versus low glucose condition. Taken together, our results indicate that the decrease in Mcl-1 levels upon glycolysis block was neither due to transcriptional nor posttranslational modification.
Mcl-1 is regulated through inhibition of its translation upon glycolysis block and AMPK activation Therefore, we investigated Mcl-1 translation in this setting. To test whether glycolysis inhibition has an effect on the eIF4F assembly and cap structure recognition process, eIF4E and associated factors were isolated with m 7 -GTP (guanosine 5 0 -triphosphate)-sepharose beads (Amersham Biosciences, Fairfield, CT, USA), which mimics the mRNA cap structure. As shown in Figure 7a , the amount of inhibitory 4E-BP1 associated with eIF4E increased dramatically under glucose-free as under 2DG conditions, indicating a decrease in translation rates in these conditions.
To verify Mcl-1 translation specifically upon glycolysis inhibition, we monitored its polysome distribution were assessed by western blot using a phospho-specific antibody. Inhibition of the mTOR pathway was assessed using a phospho-specific antibody against Thr 389 of p70-S6kinase. Total AMPK and total p70-S6K were used as loading controls. (b) Cells were cultured in regular medium and incubated for 16 h with 1 mM AICAR (AMPK activator). A 16 h glucose deprivation is used as a positive control. Cells were then treated by 10 ng/ml of anti-Fas for 6 h. in control versus glucose-free or 2DG treatment (Figure 7b ). Glycolysis inhibition produced a large redistribution of heavy polysomes in favor of the lighter polysomes and free ribosome subunits ( Figure 7b ). As presented in Figures 7c-d , Mcl-1 mRNA is redistributed from heavy polysomes (fraction 7-12) toward lighter polysomes, monosomes (80S) and free subunits (60S and 40S, fraction 3-6) indicating a block in Mcl-1 translation. Under the same condition, translation of a control mRNA (b-actin) was either not affected (2DG) or significantly less affected (in the absence of glucose) compared with Mcl-1. Very importantly, to extend our observation, we performed the same analysis using the AMPK activator, AICAR. In Figure 7e and Supplementary Figure 4 , Mcl-1 but not b-actin translation is decreased, therefore underlying the specificity of its inhibition.
Taken together, those results indicate that the Mcl-1 decrease observed upon glycolysis inhibition is mediated through the AMPK/mTOR control of its translation.
Discussion
Cancer cells are from diverse origins; nevertheless, most of them share one important feature, that is, they have a high rate of glycolysis, regardless of their oxygen supply. This notion implies a stringent dependence of these cells on extracellular glucose for energy production. More than a decade ago, TRAIL was identified as a powerful activator of programmed cell death in tumor cells while sparing normal cells (Kruyt, 2008) . Nevertheless, 50% of all tumor cells are resistant to TRAIL-induced death for unclear reasons, suggesting that many patients will be nonresponders (Koschny et al., 2007) . Therefore, identification of the mechanism leading to increased sensitivity to the tumor-killing effects of DR is of great importance.
In this study, we addressed the effect of glucose metabolism inhibition on DR-induced apoptosis of tumor cells. Our results indicate that Jurkat, HeLa and U937 cells can be markedly sensitized to DR-induced apop- tosis (Fas and TRAIL receptors) either by glucose removal or by the use of a nonmetabolizable form of glucose, such as 2DG (Figure 1 ). We established a central role for the energy supply (that is, ATP). Those cells, as most cancer cells, are exclusively dependent on glycolysis for ATP production (not shown); therefore, glucose metabolism inhibition was associated with major ATP depletion (Figure 2 ) leading to AMPK activation and mTOR inhibition (Figure 3a) . Implication of the AMPK-mTOR pathway in sensitizing cells to DR-induced apoptosis was supported by the fact that (1) AMPK was found activated and mTOR inhibited under conditions of glucose metabolism inhibition (Figure 3a ), (2) two different AMPK activators (metformin and AICAR) and a potent mTOR inhibitor (rapamycin) could mimic DR sensitization under normal glucose conditions (Figures 3b,c and e) and (iii) an AMPK inhibitor (compound c) could prevent the sensitization to DR-induced apoptosis under low glucose conditions (Figure 3d ). Despite the fact that mTOR inhibition may lead to autophagy induction in some settings, we were unable to detect any role of this pathway in the observed sensitization (not shown).
To understand where in the apoptotic pathway this sensitization occurred, we investigated mitochondrial implication in this context. We established that the mitochondria were involved in this sensitization, as Bcl-2 overexpression prevented it (Figure 4a ). We then established that the link between glucose removal and the sensitization to DR-induced apoptosis was through the antiapoptotic Bcl-2 member Mcl-1 (Figure 4b ). Mcl-1, but no other Bcl-2 member tested, decreased by 48-66% under conditions in which glucose metabolism is inhibited (Figure 4b ). We confirmed this profound downregulation of Mcl-1 induced by glucose deprivation in two other cancer cell lines (U937 and HeLa cells, Supplementary Figure 2) . Implication of the AMPKmTOR pathway in Mcl-1 decrease was confirmed using chemical activators of this pathway (Figures 4c-e) . Finally, we established that Mcl-1-specific decrease, using siRNA, was sufficient to mimic the observed sensitization in glucose containing media ( Figure 5 ).
Some studies have indicated that glucose removal induced an increase in DISC formation, leading to an increase in caspase-8 processing (Munoz-Pinedo et al., 2003) . Although we did not directly test these observations in our settings, as Bcl-2 could prevent the sensitization (Figure 4a ) and as Mcl-1 knock down by itself was sufficient to mimic the sensitization induced by glucose metabolism inhibition (Figure 5 ), we therefore concluded that Mcl-1 decrease represented the main event leading to its sensitization. In the same line, modification of FLIP levels was reported to be important for glucose removal-induced sensitization in carcinomas (Nam et al., 2002) . However, in our system, we were unable to observe any significant modification of FLIP upon glucose removal (not shown and Munoz-Pinedo et al. (2003)).
The Mcl-1 decrease observed during glucose removal was neither due to a transcriptional nor a posttranslational regulation by caspases or proteasome (Figure 6 ). Figures 6c and d) . In addition, Mcl-1 clearance was not significantly affected by glucose removal. Indeed the rate of Mcl-1 decrease upon protein synthesis block was equivalent in the presence or absence of glucose (Figures 6e and f) . Altogether, this strongly suggested that Mcl-1 degradation was not the main mechanism leading to the observed decrease under low glucose conditions. To further support our conclusion, we specifically investigated the role of GSK-3 in this Mcl-1 decrease. GSK-3 phosphorylation of Mcl-1 was recently suggested as an important pathway controlling Mcl-1 expression by proteasome degradation (Maurer et al., 2006) especially upon upregulation of the glycolytic pathway (Zhao et al., 2007) . GSK-3 implication in our model was ruled out as we did not observe any difference in its activation (that is, dephosphorylation) and as none of two potent GSK-3 inhibitors could prevent the sensitization (Supplementary Figure 3) .
Collectively, these findings strongly argue against the possibility that glucose metabolism inhibition act at the posttranslational level to diminish Mcl-1 protein stability.
For all these reasons, we investigated translation rates in glucose-deprived or 2DG-treated cells. As presented in Figure 7 , a translational inhibition of Mcl-1 is clearly visible in those settings. In addition, the fact that AICAR could prevent Mcl-1 translation (Figure 7e and Supplementary Figure 4) underlines the implication of the AMPK pathway (see model in Figure 8 ). Mcl-1 is an antiapoptotic member of the Bcl-2 family that antagonizes BH3-only proteins (including Puma, Bim). Several lines of evidence have suggested that Mcl-1 decrease works in parallel with Puma and/or Bim to initiate apoptosis (Han et al., 2006) . It would therefore be interesting to investigate those proapoptotic members upon inhibition of glucose metabolism. Among the antiapoptotic members of the Bcl-2 family, Mcl-1 is of particular interest because (1) it contains a G þ C rich (>70%) 5 0 untranslated region (Mills et al., 2008) and (ii) given that Mcl-1 protein is highly regulated and rapidly degraded (Zhong et al., 2005; Maurer et al., 2006) , inhibition of its synthesis would lead to a major decrease in protein level. Finally, several lines of evidence are in support of Mcl-1 regulation at the translational level. Studies have suggested that, in other contexts, Mcl-1 is a potential downstream target of eIF4E (Wei et al., 2006; Wendel et al., 2007; Mills et al., 2008) . Recently Wei et al. (2006) described the ability of rapamycin (mTOR inhibitor) to induce Mcl-1 but not Bcl-2 or Bcl-XL block in protein translation. Moreover, mir-29b (microRNAs are acting as endogenous sequence that specifically suppress translation) was recently reported to regulate Mcl-1 expression, and its enforced expression made cancer cells sensitive to TRAIL (Mott et al., 2007) .
In conclusion, since its discovery, TRAIL has attracted great interest as a cancer-specific cytotoxic agent with virtually no off-target effects; however, a limiting factor in the use of TRAIL in cancer treatment is the suggestion that a significant percentage of human tumors may be insensitive, suggesting that many patients will be nonresponders. In this study, we established that metformin, AICAR and rapamycin could mimic the effect of glucose removal on the sensitization to DR-induced apoptosis. Metformin is a widely used antidiabetic drug now prescribed to almost 120 million of people in the world. Besides its wellcharacterized effect, metformin has already been reported to reduce the risk of cancer (Evans et al., 2005) and rapamycin has shown promising effects against some cancers (Guertin and Sabatini, 2007) . Therefore, we could envision that a combined use of metformin or rapamycin with TRAIL may represent a very powerful method to selectively kill tumor cells.
Materials and methods
Reagent and antibodies
Anti-Mcl-1, -Erk2 and -Hsp60 were purchased from Santa-Cruz Santa Cruz (Santa Cruz, CA, USA). Other antibodies were purchased from Cell Signaling Technology (Beverlu, MA, USA). Ac-DEVD-AMC was obtained from Alexis Biochemicals (Lausan, Switzerland), anti-Fas (CH-11) was purchased from Upstate Biotechnology (Lake Placid, NY, USA), human recombinant TRAIL from R&D (Minneapolis, MN, USA), recombinant Annexin V-fluorescein isothiocyanate from Invitrogen (Carlsbad, CA, USA), AICAR from TRC (North York, DN, Canada), compound C from Calbiochem (San Diego, CA, USA) qVD-OPH from SM Biochemicals (Yorba Linda, CA, USA) and other drugs were purchased from Sigma (St Louis, MO, USA). Under glycolysis block (in glucose-free medium or in presence of 2DG), AMPK is activated through a decrease in ATP levels. AMPK activation leads to mTOR inhibition, decrease in p70-S6 Kinase phosphorylation and stabilization of the 4E-BP-eIF4E complex. Altogether this leads to an inhibition of translation resulting in Mcl-1 protein decrease. The decrease of this anti-apoptotic member of Bcl-2 family sensitizes cells to deathreceptor induced apoptosis via a mitochondrial amplification of the death cascade. AMPK activators (AICAR and metformin) or inhibitor (compound C) and mTOR inhibitor (rapamycin) are also presented on this model. AMPK, adenosine monophosphateactivated protein kinase; ATP, adenosine triphosphate; mTOR, mammalian target of rapamycin; 2DG, 2-deoxyglucose; 4E-BP, 4E-binding protein; eIF4E, eukaryotic initiation factor-4E;
Cell culture U937 and Jurkat cells were cultured in RPMI 1640 medium supplemented with 5% fetal calf serum, 2 mM L-glutamine, 1 mM pyruvate and 100 Units/ml each of penicillin and streptomycin. HeLa cells were cultured in Dulbecco's modied Eagle's medium supplemented as previously (with fetal calf serum 10%).
For glucose deprivation, cells were cultivated in glucose-free RPMI (Jurkat, U937) or Dulbecco's modied Eagle's medium (HeLa) supplemented as previously with 5 or 10% of fetal calf serum, respectively. When indicated, 2DG was added in glucose containing media (10 mM for Jurkat and U937 or 25 mM for HeLa cells).
Annexin V assay
After treatment, cells were resuspended in 200 ml of buffer (150 mM NaCl, 10 mM Hepes, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 ) and incubated with recombinant Annexin V-fluorescein isothiocyanate for 10 min at room temperature. A volume of 0.5 mg/ml of propidium iodide was then added, and samples were analyzed immediately by flow cytometry using a FACScan (Becton Dickinson, Franklin Lake, NJ, USA). Percentage of apoptotic cells corresponds to Annexin V-positive cells and Annexin V/propidium iodide double positive cells.
Cell lysate and western blot analysis Briefly, after treatment, cells were collected, washed in phosphate-buffered saline and lysed as described previously (Lavallard et al., 2009) . When indicated, western blot quantification was made using ImageJ software.
DEVDase activity
A total of 20 mg of protein (in duplicate) was incubated with 0.2 mM of Ac-DEVD-AMC in 50 mM HEPES pH 8; 150 mM NaCl; 20 mM ethylenediaminetetraacetic acid±1 mM Ac-DEVD-CHO. Caspase activity was determined at 460 nm, and specific activities were expressed in DOD per minute and per milligrams of protein.
RNA interference and cell nucleofection
Mcl-1 knockdown was obtained using a mix of two specific Mcl-1 siRNAs. Briefly 5 Â 10 6 cells were nucleofected using solution V of Amaxa Biosystems (Cologne, Germany) with 75 ng of each siRNA targeting Mcl-1 (5 0 -CUGUAAGCCUC AGUACUGUTT-3 0 and 5 0 -GAAGCAAAGUUCAGUUUC ATTT-3 0 ) or 150 ng of siRNA control (5 0 -GAUUUAUGCA ACAAUAGUA-3 0 ).
ATP determination
Adenosine triphosphate was determined using ATPlite 1 step kit (Perkin-Elmer, Walthman, MA, USA). After treatment, 5000 cells were plated in triplicate in 100 ml of medium. A volume of 100 ml of ATPlite reagent was then added, and luminescence was measured using a Berthold luminometer (Berthold, Thoiry, France). The amount of ATP is expressed in arbitrary units per cell.
Real-time PCR mRNAs were isolated using Trizol reagent (Invitrogen). mRNA expression level was quantified by real-time one-step PCR performed in an ABI PRISM 5700 Sequence Detector System (Applied Biosystems, Foster City, CA, USA) using the SYBRGreen detection protocol. mRNA values are expressed as arbitrary units (see Marchetti et al. (2009) ).
Lactate measurement
Lactate was measured using Trinity Biotech Detection Kit (Trinity Biotech, Theale, UK) according to the manufacturer's instructions and expressed in nmol per cell.
Polysome profiles and northern blot analysis After treatment, cycloheximide (100 mg/ml) was added in the media for 10 min, then the cells were washed with phosphatebuffered saline containing cycloheximide and lysed in hypotonic buffer: 1.5 mM KCl, 2.5 mM MgC1 2 , 5 mM Tris-HCl pH 7.4, 100 mg/ml cycloheximide, 0.5% sodium deoxycholate, 0.5% Triton X-100, 3 mM dithiothreitol and 120 units per ml of RNasin. The extracts were cleared (6000 r.p.m.-8 min-4 1C), and 1 mg/ml of heparin was added to the supernatant. In all, 5 mg of protein was run on a 17.1-51% sucrose gradient in a SW41Ti Beckman rotor (36 000 r.p.m.-120 min-4 1C) (Beckman, Palo Alto, CA. USA). To analyze the RNAribosome complex, gradients were then fractionated in 12 with continuous recording of OD 260 nm along the gradient. RNA isolation and northern blot analysis of each fractions were performed as described previously (Shima et al., 1998) . Northern blots were hybridized with specific Mcl-1 and b-actin probes (Mcl-1: 5 0 -GAT-GCA-GCT-TTC-TTG-GTT-TAT-GGT-CTT-CAA-GTG-TTT-AGC-CAC-AAA-GGC-AC-, b-actin: 5 0 -TCA-CAC-CCT-GGT-GCC-TAG-GGC-GGC-CCA-CGA-TGG-AGG-GGA-A-3 0 ). Quantification was made using Storm Image quant software.
7-Methyl-GTP cap binding assay
After treatment, 2 Â 10 7 cells were washed in phosphatebuffered saline then resuspended in 400 ml of 20 mM Tris pH 7.5, 100 mM KCl, 20 mM b-glycerophosphate, 1 mM dithiothreitol, 250 mM Na 3 VO 4 , 10 mM NaF, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride and lysed with four successive freeze-thaw cycles. After centrifugation (13 000 g-10 min-4 1C), 450 mg of protein was applied to 50 ml of m 7 -GTPsepharose 4B beads and incubated for 2 h at 4 1C. The beads were washed then boiled in Laemmli sample buffer. After SDS-PAGE resolution, the association of 4E-BP1 with eIF4E was detected by western blot.
